Investors

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

  • January 20, 2014 at 12:00 AM EST
    Halifax, Nova Scotia; January 20, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.   Dr.
  • January 20, 2014 at 12:00 AM EST
    Halifax, Nova Scotia; January 20, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced that pursuant to terms and conditions of the Company's stock option plan, it has granted 1,731,500 stock options
  • January 9, 2014 at 12:00 AM EST
    Halifax, Nova Scotia; January 9, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at the 6th Annual Biotech Showcase Conference.
  • December 16, 2013 at 12:00 AM EST
    Halifax, Nova Scotia; December 16, 2013 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced the election of Marc Mansour, Ph.D., the Company’s Chief Operating Officer (COO), to its board of directors.
  • November 29, 2013 at 12:00 AM EST
    Halifax, Nova Scotia ; November 29, 2013 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today released its financial and operational results for the quarter ended September 30, 2013.
  • November 21, 2013 at 12:00 AM EST
    Halifax, Nova Scotia; November 21, 2013 – Immunovaccine Inc. (“Immunovaccine” or “IMV”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, has closed the previously announced private placement of its securities, raising gross proceeds of $4.2 million (the “ Private Placement ”).
  • October 28, 2013 at 12:00 AM EDT
    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. Halifax, Nova Scotia, October 28, 2013 – Immunovaccine Inc.
  • October 11, 2013 at 12:00 AM EDT
    Halifax, Nova Scotia; October 11, 2013 – Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX-V: IMV), a clinical stage vaccine company, has retained B & D Capital Partners ("B & D") to provide strategic investor relations services.
  • September 9, 2013 at 12:00 AM EDT
    Data demonstrates 100% protection against a lethal anthrax challenge after a single vaccination Animals produced sustained protective antibodies within 28 days following vaccination with the lowest antigen dose tested Halifax, Nova Scotia; September 9, 2013 – Immunovaccine Inc.
  • September 3, 2013 at 12:00 AM EDT
    Halifax, Nova Scotia; September 3, 2013 – Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX-V: IMV), a clinical stage vaccine company, today announced that Albert Scardino has been appointed executive chairman and that Marc Mansour, Ph.D.